The April 27, 2026 announcement from Veradermics confirmed what investors and hair loss patients had been waiting months to hear: VDPHL01 works. Study ‘302’ met every primary and key secondary endpoint. But one positive trial, however well-designed, does not get a drug approved. Here is what has to happen next — and why the next 18 months are the most consequential in VDPHL01’s development history.
Study ‘302’ read out positive on April 27, 2026 — the full results breakdown is here. But one positive trial does not get a drug approved. Veradermics has two more pivotal studies running, and the next 18 months will determine whether VDPHL01 reaches pharmacy shelves — and for whom.
Study ‘304’: The Confirmatory Male Trial
Study ‘304’ is Veradermics’ second pivotal Phase 3 trial in male pattern hair loss, and by design it carries more regulatory weight than Study ‘302’.
- Enrollment: 536 men — larger than Study ‘302’
- Status: Fully enrolled as of February 2026
- Results expected: Second half of 2026
- Role: Primary basis for the FDA NDA submission in male AGA
In February, Veradermics announced enrollment completion across all male Phase 3 studies — approximately 1,000 male patients enrolled in total between studies ‘302’ and ‘304’. That is a substantial safety and efficacy dataset, and it reflects a development program built with regulatory approval — not just proof-of-concept — as the explicit goal.
If Study ‘304’ results confirm what Study ‘302’ demonstrated, Veradermics expects to file a New Drug Application with the FDA in early 2027.
Study ‘306’: The Women’s Trial — and Why It Matters More Than People Realize
This is the part of VDPHL01’s development program that has received the least attention — and arguably deserves the most.
Study ‘306’ is a Phase 2/3 trial evaluating VDPHL01 in women with female pattern hair loss (FPHL). As of April 2026, the trial is actively recruiting, targeting over 500 female participants.
To understand why this is significant, consider the current treatment landscape for women with pattern hair loss:
- Minoxidil (topical): FDA-approved for women, but applied to the scalp daily and associated with scalp irritation and unwanted facial hair growth
- Finasteride / Dutasteride: Not approved for women, contraindicated in women of childbearing age due to teratogenic risk
- Low-dose oral minoxidil (off-label): Used increasingly, but without controlled trial data and with cardiovascular liability at higher doses
There is currently no FDA-approved oral prescription treatment for female pattern hair loss. If Study ‘306’ succeeds, VDPHL01 would be exactly that — the first of its kind. The commercial and clinical implications for the estimated 30 million American women with androgenetic alopecia are difficult to overstate.
“If approved, VDPHL01 would be the only FDA-approved oral non-hormonal treatment for pattern hair loss in both male and female patients.”
Veradermics, Inc. — official company statement
The FDA Path: What Approval Actually Requires
An NDA for VDPHL01 will need to demonstrate safety and efficacy through the full clinical package — Phase 2 data, Study ‘302’, and Study ‘304’ at minimum. Here is the projected sequence:
| Milestone | Expected Timing |
|---|---|
| Study ‘304’ topline results | H2 2026 |
| NDA submission to FDA | Early 2027 |
| FDA review period (standard: ~12 months) | Throughout 2027 |
| Potential FDA approval | Late 2027 – Early 2028 |
| Study ‘306’ (women) results | TBD — trial actively recruiting |
The FDA’s standard review period for a standard NDA is approximately 10–12 months from submission. If Veradermics qualifies for Priority Review — which is possible given there have been no new approved prescription treatments for pattern hair loss in nearly 30 years — that window could compress to 6 months.
VDPHL01’s patent portfolio extends to at least 2043, giving Veradermics significant exclusivity runway if and when approval is granted.
What Could Go Wrong
Study ‘302’ was positive, but confirmatory trials do not always replicate Phase 2/3 results. The key risks between now and approval:
- Study ‘304’ fails to confirm: If the efficacy or safety profile diverges significantly from Study ‘302’, the NDA becomes complicated or delayed
- FDA requests additional data: A Complete Response Letter (CRL) could push approval back by 12–24 months
- Safety signals at scale: The combined 1,000-patient male dataset may surface adverse events not visible in Study ‘302’ alone
- Manufacturing / CMC issues: The extended-release gel matrix is a proprietary formulation; scale-up and consistency requirements add regulatory complexity
None of these are unusual risks for a late-stage biopharmaceutical program — they are the standard obstacles between positive Phase 3 data and a drug on pharmacy shelves.
The Bottom Line
The roadmap from here is clear: Study ‘304’ results in H2 2026 → NDA filing early 2027 → potential approval late 2027 or early 2028. Separately, Study ‘306’ for women is running in parallel and could extend the approved indication — and the addressable market — significantly beyond what the male trials alone would support.
For the 80 million Americans living with pattern hair loss, the next 18 months are worth watching closely.
Sources: Veradermics press release, Business Wire (April 27, 2026); Enrollment completion announcement, Business Wire (February 9, 2026); BioPharma Dive.